- Palestinians turn to local soda in boycott of Israel-linked goods
- Typhoon Man-yi bears down on Philippines still reeling from Usagi
- UK growth slows in third quarter, dealing blow to Labour government
- Chris Wood hits quickfire double in NZ World Cup qualifying romp
- Markets struggle at end of tough week
- China tests building Moon base with lunar soil bricks
- Film's 'search for Palestine' takes centre stage at Cairo festival
- Oil execs work COP29 as NGOs slam lobbyist presence
- Gore says climate progress 'won't slow much' because of Trump
- 'Megaquake' warning hits Japan's growth
- Stiff business: Berlin startup will freeze your corpse for monthly fee
- Wars, looming Trump reign set to dominate G20 summit
- Xi, Biden attend Asia-Pacific summit, prepare to meet
- Kyrgios to make competitive return at Brisbane next month after injuries
- Dominican Juan Luis Guerra triumphs at 25th annual Latin Grammys
- Landslide win for Sri Lanka president's leftist coalition in snap polls
- Australian World Cup penalty hero Vine takes mental health break
- As Philippines picks up from Usagi, a fresh storm bears down
- Tropical Storm Sara pounds Honduras with heavy rain
- Pepi gives Pochettino win for USA in Jamaica
- 'Hell to heaven' as China reignite World Cup hopes with late winner
- Rebel attacks keep Indian-run Kashmir on the boil
- New Zealand challenge 'immense but fantastic' for France
- Under pressure England boss Borthwick in Springboks' spotlight
- All Blacks plan to nullify 'freakish' Dupont, says Lienert-Brown
- TikTok makes AI driven ad tool available globally
- Japan growth slows as new PM readies stimulus
- China retail sales pick up speed, beat forecasts in October
- Asian markets fluctuate at end of tough week
- Gay, trans people voicing -- and sometimes screaming -- Trump concerns
- Argentina fall in Paraguay, Brazil held in Venezuela
- N. Korean leader orders 'mass production' of attack drones
- Pakistan's policies hazy as it fights smog
- Nature pays price for war in Israel's north
- New Zealand's prolific Williamson back for England Test series
- Mexico City youth grapple with growing housing crisis
- After Trump's victory, US election falsehoods shift left
- Cracks deepen in Canada's pro-immigration 'consensus'
- Xi inaugurates South America's first Chinese-funded port in Peru
- Tyson slaps Paul in final face-off before Netflix bout
- England wrap-up T20 series win over West Indies
- Stewards intervene to stop Israel, France football fans clash at Paris match
- Special counsel hits pause on Trump documents case
- Japan's Princess Mikasa, great aunt to emperor, dies aged 101
- Cricket at 2028 Olympics could be held outside Los Angeles
- Trump names vaccine skeptic RFK Jr. to head health dept
- Ye claims 'Jews' controlling Kardashian clan: lawsuit
- Japan into BJK Cup quarter-finals as Slovakia stun USA
- Sri Lanka president's party headed for landslide: early results
- Olympics 'above politics' say LA 2028 organisers after Trump win
RBGPF | 100% | 61.84 | $ | |
CMSC | -0.24% | 24.55 | $ | |
SCS | -0.75% | 13.27 | $ | |
BTI | 0.2% | 35.49 | $ | |
GSK | -2.09% | 34.39 | $ | |
RELX | -0.37% | 45.95 | $ | |
NGG | 0.4% | 62.37 | $ | |
BCC | -1.57% | 140.35 | $ | |
CMSD | -0.02% | 24.725 | $ | |
RIO | -0.31% | 60.43 | $ | |
BP | 1.65% | 29.05 | $ | |
BCE | -1.38% | 26.84 | $ | |
RYCEF | -4.71% | 6.79 | $ | |
JRI | -0.23% | 13.21 | $ | |
AZN | -0.38% | 65.04 | $ | |
VOD | -0.81% | 8.68 | $ |
US drug regulator limits use of J&J Covid vaccine
The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition.
The vaccine, which was authorized as a single shot, is less protective than those developed by Pfizer and Moderna, and in December the Centers for Disease Control and Prevention advised the public to steer clear.
Thursday's decision by the Food and Drug Administration builds on that recommendation by limiting the J&J vaccine's emergency use authorization.
"Today's action demonstrates the robustness of our safety surveillance systems and our commitment to ensuring that science and data guide our decisions," said FDA scientist Peter Marks in a statement.
Sixty US cases of thrombosis with thrombocytopenia syndrome (TTS), which produces rare and potentially life-threatening blood clots with low levels of blood platelets, had been reported by March 18, with nine deaths.
Symptoms begin approximately one to two weeks following administration, and the condition -- which can cause life-long impacts even when not fatal -- occurs more frequently in premenopausal women.
Concerns over the vaccine have already limited uptake: Only 18.7 million doses have been administered in the United States, or about 3.2 percent of the total 577 million.
But the FDA stopped short of an outright de-authorization, with Marks acknowledging the impact a ban might have on global use of the vaccine, as well as concerns some may have specifically against mRNA vaccines, rather than the adenovirus vector platform J&J uses.
There are certain health-based justifications for not taking an mRNA vaccine -- such as rare instances of heart inflammation in adolescent males and young men -- although these are usually transient in nature and the vast majority affected recover completely.
However, anti-vaccine groups have also raised more general objections against mRNA vaccines, which are tied to conspiracy theories.
Although those types of concerns are not rooted in evidence, the exemption to use J&J's shot nonetheless extends to "individuals who have personal concerns with receiving mRNA vaccines and would otherwise not receive a Covid-19 vaccine," the FDA's statement said.
R.Chavez--AT